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OBJECTIVES: Pathological complete response has shown a better prognosis for patients with locally advanced
rectal cancer after preoperative chemoradiotherapy. However, correlations between post-chemoradiotherapy
clinical factors and pathologic complete response are not well confirmed. The aim of the current study was to
identify post-chemoradiotherapy clinical factors that could serve as indicators of pathologic complete response
in locally advanced rectal cancer.
METHODS: This study retrospectively analyzed 544 consecutive patients with locally advanced rectal cancer
treated at Sun Yat-sen University Cancer Center from December 2003 to June 2014. All patients received
preoperative chemoradiotherapy followed by surgery. Univariate and multivariate regression analyses were
performed to identify post-chemoradiotherapy clinical factors that are significant indicators of pathologic
complete response.
RESULTS: In this study, 126 of 544 patients (23.2%) achieved pathological complete response. In multivariate
analyses, increased pathological complete response rate was significantly associated with the following factors:
post-chemoradiotherapy clinical T stage 0-2 (odds ratio=2.098, 95% confidence interval=1.023-4.304, p=0.043),
post-chemoradiotherapy clinical N stage 0 (odds ratio=2.011, 95% confidence interval=1.264-3.201, p=0.003),
interval from completion of preoperative chemoradiotherapy to surgery of 47 weeks (odds ratio=1.795, 95%
confidence interval=1.151-2.801, p=0.010) and post-chemoradiotherapy carcinoembryonic antigen p2 ng/ml
(odds ratio=1.579, 95% confidence interval=1.026-2.432, p=0.038).
CONCLUSIONS: Post-chemoradiotherapy clinical T stage 0-2, post-chemoradiotherapy clinical N stage 0, interval
from completion of chemoradiotherapy to surgery of 47 weeks and post-chemoradiotherapy carcino-
embryonic antigen p2 ng/ml were independent clinical indicators for pathological complete response. These
findings demonstrate that post-chemoradiotherapy clinical factors could be valuable for post-operative
assessment of pathological complete response.
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’ INTRODUCTION
Currently, preoperative chemoradiotherapy (CRT) fol-
lowed by total mesorectal excision (TME) is the standard
treatment for patients with locally advanced rectal cancer
(LARC) to improve local disease control and sphincter
preservation rate (1,2). Following preoperative chemother-
apy, variable responses have been observed among indivi-
duals, with a range of 12% to 40% of cases achieving
pathological complete response (pCR) (3-5). Patients achiev-
ing pCR after CRT have a lower incidence of recurrence and
more favorable long-term survival than those without pCR
(6,7). Additionally, due to the associated relatively long-term
survival, tumor complete response allows the adoption of a
‘‘wait-and-see’’ policy for patients undergoing neoadjuvant
CRT instead of necessitating immediate surgery (8,9). There-
fore, it is of considerable clinical importance to identify
significant factors that can successfully predict pCR after
preoperative CRT. Although many techniques have been
applied towards this goal, correlations between post-CRTDOI: 10.6061/clinics/2016(08)07
Copyright & 2016 CLINICS – This is an Open Access article distributed under the
terms of the Creative Commons License (http://creativecommons.org/licenses/by/
4.0/) which permits unrestricted use, distribution, and reproduction in any
medium or format, provided the original work is properly cited.
No potential conflict of interest was reported.
449
CLINICAL SCIENCE
clinical factors and pCR are seldom reported and remain
poorly defined (10). To identify significant post-CRT clinical
factors associated with pCR, we conducted the current study
using a large cohort of patients undergoing CRT and surgery
at a single center.
’ PATIENTS AND METHODS
Patient selection
This study included a total of 577 consecutive patients with
rectal cancer who underwent preoperative CRT followed by
surgery fromDecember 2003 through June 2014 at Sun Yat-sen
University Cancer Center, China. The following inclusion
criteria were applied: (1) histologically confirmed rectal
adenocarcinoma; (2) cT3-4 or N+ disease before CRT; (3) no
other anti-tumor therapy was received before CRT; and (4) no
distant metastatic disease. Thirty-one patients were excluded
from this study due to distant metastatic disease before CRT
and an additional two patients who were confirmed to have
adenosquamous carcinoma were also eliminated. This left a
total of 544 individuals who were included for analysis. The
detailed clinical data of the eligible patients were reviewed
using our electronic medical record system. Prior to CRT and
surgery, informed consent was obtained from each patient.
The study was undertaken in accordance with the ethical
standards of the World Medical Association Declaration of
Helsinki and study approval was obtained from independent
ethics committees at Sun Yat-Sen University Cancer Center.
Treatment
All of the subjects underwent preoperative CRT. Radiation
therapy (RT) was administered via three-dimensional con-
formal radiation therapy (3D-CRT) or intensity-modulated
radiation therapy (IMRT). The patients were scheduled to
receive a total irradiation dose of 46.0-50.4 Gy to the pelvic
area, delivered in 1.8-2.0 Gy fractions daily on five
consecutive days per week for 5-6 weeks. If a patient could
not tolerate the full dose or suffered from severe toxic effects,
the RTwas stopped. Patients who were reluctant to undergo
surgery were delivered a radical dose of RT.
One of the following chemotherapeutic regimens was
delivered concurrently with the RT: (1) XELOX regimen
consisting of 130 mg/m2 oxaliplatin administered intrave-
nously on day 1 and 1,000 mg/m2 capecitabine administered
orally twice daily on days 1-14 for a 3-week cycle;
(2) FOLFOX regimen consisting of 85 mg/m2 oxaliplatin
and 400 mg/m2 leucovorin administered intravenously over
2 hours on day 1, 400 mg/m2 5-FU administered intravenously
on day 1 and 1200 mg/m2 5-FU administered intravenously
for 2 days for a 2-week cycle; or (3) 825 mg/m2 capecitabine
administered orally twice daily during RT without weekend
breaks.
All subjects were scheduled for radical resection 6–8 weeks
after the completion of preoperative CRT. If bowel obstruc-
tion or perforation occurred after CRT, emergent surgery was
performed immediately. Surgery was delayed in the event of
grade 3 or 4 toxicity. The surgical procedure used depended
on tumor location and invasive extent; TME was performed
whenever possible.
Evaluation
Post-CRT clinical evaluation was performed at the
6th week after completion of CRT and included a combina-
tion of physical examination, post-CRT carcinoembryonic
antigen (CEA) test, colonoscopy, transrectal ultrasonography
(EUS), chest computed tomography (CT) and abdominal and
pelvic nuclear magnetic resonance (MRI). Disease stage was
classified according to the 2010 American Joint Committee
on Cancer/International Union Against Cancer (AJCC/
UICC) staging system. According to EUS images, post-CRT
clinical (yc) T stage 0 was defined as no tumor signs in the
bowel wall; ycT stage 1 was defined as a tumor signal
confined to the submucosa; and ycT stage 2 was defined as a
malignancy that had invaded the muscularis propria. Using
MR images, ycN stage 0 was defined as the absence of
metastatic lymph nodes; ycN stage 1 and ycN stage 2 were
respectively defined as the presence of 1-3 and43 metastatic
lymph nodes, which appeared irregular in shape, showed
enhancement and possessed a diameter45 mm; ycT stage 3
was defined as a malignancy that broke through the
muscularis propria; and ycT stage 4 was defined as a tumor
that had invaded adjacent organs. All radiological reports
were confirmed by two independent radiologists. Post-
operative final tumor pathological staging was also eval-
uated by two independent pathologists. pCR was defined as
the absence of viable tumor cells, with only fibrotic masses or
acellular mucin pools present in proximity to the primary
tumor and lymph nodes (11). Patients confirmed as having
achieved pCR were classified as the pCR cohort, while the
remaining patients formed the non-pCR cohort.
Statistical analysis
Data were analyzed using SPSS version 17.0 (Chicago, IL,
USA). Continuous variables were shown as the median
(range) or the mean (standard deviation) and categorical
variables were presented as percentages. All continuous and
polytomous variables were dichotomized by a cut-point
prior to univariate and multivariate analyses. Univariate
comparisons of factors were performed using the chi square
test or Fisher’s exact test for categorical variables and an
unpaired t-test for continuous variables. Factors with statistical
significance in univariate analyses were included in multi-
variate analyses. Multivariate analyses were performed using
logistic regression to identify significant post-CRT clinical
indicators and therapeutic factors for pCR. All tests were two-
tailed and po0.05 was considered statistically significant.
’ RESULT
Clinical demographics
A total of 544 patents, 361 men (66.4%) and 183 women
(33.6%) were enrolled. The median patient age was 55 years
(range 12-81 years). Before CRT, 170 patients (31.1%)
presented clinical stage II disease and 374 (68.7%) presented
clinical stage III disease. The clinical demographics and
treatment results are presented in Table 1. The median
radiation dose was 50 Gy (range 30–70 Gy). Regarding the
concurrent chemotherapy, 473 (87.0%) patients received
the XELOX regimen, while 49 (9.0%) patients received the
FOLFOX regimen, and 22 (4.0%) were given oral capecitabine
alone. After CRT, the median distance of the inferior tumor
margin from the anal verge (DAV) was 5 cm (range 0–15 cm)
and the median interval from completion of CRT to surgery
was 51 days (range 7–78 days). All patients underwent
surgery: 318 (58.5%) underwent anterior resection, 196 (36.0%)
underwent abdominal perineal resection, 14 (2.6%) underwent
the Hartmann procedure and the remaining 16 (2.9%) patients
underwent unsuccessful tumor resection and subsequently
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received palliative colostomy. After the comprehensive treat-
ment, 126 patients (23.2%) obtained pCR. The general clinical
parameters, including age, gender, pre- and post-CRT DAV,
pre- and post-CRT body mass index (BMI), pre-CRT clinical
tumor-node-metastasis (TNM) stage, surgical procedure,
radiation pattern and chemotherapy regimens, were compar-
able between the pCR cohort and the non-pCR cohort.
Radiation dose (p=0.041), yc T stage (p=0.002), yc N stage
(p=0.002), ycTNM stage (p=0.001), tumor differentiation
(p=0.001), median interval from completion of CRT to surgery
(p=0.007) and post-CRT CEA level (p=0.011) were significantly
different between the two groups.
Post-CRT clinical indicators for pCR
The cut-off values for post-CRT CEA, DAV and interval
from the completion of CRT to surgery were set according to
the median values. In the univariate analyses, the potential
post-CRT clinical indicators included ycT stage, ycN stage,
post-CRT DAV, interval from completion of CRT to surgery,
Table 1 - Demographics of patients who underwent preoperative chemoradiotherapy followed by surgery and their tumor
characteristics (n=544).
Variable Total (n=544,%) pCR (n=126,%) Non-pCR (n=418,%) p-value
Gender 0.895
Male 361 (66.4) 83 (65.9) 278 (66.5)
Female 183 (33.6) 43 (34.1) 140 (33.5)
Age (years)a 55 (12-81) 55 (30-75) 55 (12-81) 0.546
Pre-CRT BMI (kg/m2)b 22.3±3.1 22.4±2.8 22.3±3.2 0.861
Pre-CRT DAV (cm)a 5 (0-15) 5 (1-12) 5 (0-15) 0.442
Tumor differentiation 0.001
Well 50 (9.2) 30 (23.8) 20 (4.8)
Moderate 370 (68.0) 70 (55.6) 300 (71.8)
Poor 124 (22.8) 26 (20.6) 98 (23.4)
cTNM stage 0.147
II 170 (31.2) 46 (36.5) 124 (29.7)
III 374 (68.8) 80 (63.5) 294 (70.3)
Chemotherapy regimen 0.228
XELOX 473 (87.0) 120 (95.2) 353 (84.4)
FOLFOX 49 (9.0) 4 (3.2) 45 (10.8)
Capecitabine 22 (4.0) 2 (1.6) 20 (4.8)
Radiation dose (Gy) 50 (30-70) 50 (30-50) 46 (30-70) 0.041
Radiation pattern 0.198
3D-CRT 230 (42.3) 47 (37.3) 183 (43.8)
IMRT 314 (57.7) 79 (62.7) 235 (56.2)
Post-CRT BMI (kg/m2)b 22.1±3.4 22.1±2.9 22.1±3.4 0.937
ycT stage 0.002
0 6 (1.1) 6 (4.8) 0
1 7 (1.3) 2 (1.6) 5 (1.2)
2 36 (6.6) 10 (7.9) 26 (6.2)
3 334 (61.4) 81 (64.3) 253 (60.5)
4 161 (29.6) 27 (21.4) 134 (32.0)
ycN stage 0.002
0 323 (59.4) 89 (70.6) 234 (56.0)
1 209 (38.4) 35 (27.8) 174 (41.6)
2 12 (2.2) 2 (1.6) 10 (2.4)
ycTNM stage 0.001
0 6 (1.1) 6 (4.8) 0
I 35 (6.4) 8 (6.3) 27 (6.5)
II 276 (50.7) 74 (58.7) 202 (48.3)
III 214 (39.3) 37 (29.4) 177 (42.3)
IV 13 (2.4) 1 (0.8) 12 (2.9)
Post-CRT DAV (cm)a 5 (0-15) 5 (1-12) 5 (0-15) 0.157
Post-CRT CEA (ng/ml)a 2.4 (0.38-387.9) 2.1 (0.4-11.7) 2.5 (0.38-387.9) 0.011
Interval from completion of CRT to surgery (weeks)a 7 (1-12) 8 (5-12) 7 (1-12) 0.007
Surgical procedure 0.506
Anterior resection 318 (58.5) 81 (64.3) 237 (56.7)
Abdominal perineal resection 196 (36.0) 44 (34.9) 152 (36.4)
Hartmann procedure 14 (2.6) 1 (0.8) 13 (3.1)
Palliative colostomy 16 (2.9) 0 16 (3.8)
BMI: body mass index, DAV: distance of inferior tumor margin from the anal verge, CEA: carcinoembryonic antigen, pCR: pathologic complete response,
cTNM stage: clinical tumor-node-metastasis classification, ycT stage: clinical tumor stage after chemoradiotherapy, ycN stage: clinical node stage after
chemoradiotherapy, ycTNM stage: clinical tumor-node-metastasis classification after chemoradiotherapy, 3D-CRT: three-dimensional conformal radiation
therapy, IMRT: intensity-modulated radiation therapy, CRT: chemoradiotherapy
a These values are presented as the median followed by the range in parentheses.
b These values are presented as the mean followed by the standard deviation in parentheses.
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radiation dose and post-CRT CEA level (Table 2). The
multivariate logistic regression analyses indicated that ycT
stage 0-2 [odds ratio (OR)=2.098, 95% confidence interval (CI)
=1.023-4.304, p=0.043], ycN stage 0 (OR=2.011, 95% CI=1.264-
3.201, p=0.003), interval from completion of CRT to surgery of
47 weeks (OR=1.795, 95%CI=1.151-2.801, p=0.010) and post-
CRT CEAp2 ng/ml (OR=1.579, 95%CI=1.026-2.432, p=0.038)
were independent factors for increased pCR (Table 3).
Table 2 - Univariate analyses of indicators for pathological complete response to preoperative chemoradiotherapy in locally advanced
rectal cancer.
Variable pCR n=126 (% of total) Non-pCR n=418 (% of total) Odds ratio (95% CI) p-value
Gender 0.895
Male 83 (23.0) 278 (77.0) Reference
Female 43 (23.5) 140 (76.5) 1.029 (0.676-1.567)
Age (years) 0.546
p60 83 (24.0) 263 (76.0) Reference
460 43 (21.7) 155 (78.3) 0.879 (0.579-1.336)
Post-CRT BMI (kg/m2)a 0.143
p25 103 (35.4) 188 (64.6) Reference
425 23 (22.1) 81 (77.9) 0.655 (0.372-1.53)
Chemotherapy regimen 0.129
Capecitabine 2 (0.09) 20 (0.91) Reference
XELOX and FOLFOX 124 (23.8) 398 (76.2) 3.116 (0.718-13.516)
Radiation pattern 0.198
3D-CRT 47 (20.4) 183 (79.6) Reference
IMRT 79 (25.2) 235 (74.8) 1.309 (0.869-1.971)
Dose of radiotherapy (Gy) 0.044
o50 51 (19.4) 212 (80.6) Reference
X50 75 (26.7) 206 (73.3) 1.513 (1.010-2.267)
ycT stage 0.006
3-4 108 (21.8) 387 (78.2) Reference
0-2 18 (36.7) 31 (63.3) 2.414 (1.281-4.547)
ycN stage 0.002
1-2 37 (16.7) 184 (83.3) Reference
0 89 (27.6) 234 (72.4) 1.952 (1.267-3.009)
Post-CRT DAV (cm) 0.044
45 73 (23.5) 283 (76.5) Reference
p5 53 (28.2) 135 (71.8) 1.522 (1.011-2.291)
Tumor differentiation 0.510
Well and moderate 100 (23.8) 320 (76.2) Reference
Poor 26 (21.0) 98 (79.0) 0.849 (0.522-1.382)
Interval from completion of CRT to surgery (weeks) 0.020
p7 43 (18.3) 192 (81.7) Reference
47 83 (26.9) 226 (73.1) 1.640 (1.082-2.485)
Post-CRT CEA (ng/ml)b 0.037
42 64 (20.3) 251 (79.7) Reference
p2 53 (28.5) 133 (71.5) 1.563 (1.027-2.379)
CI: confidence interval, BMI: body mass index, DAV: distance of inferior tumor margin from the anal verge, CEA: carcinoembryonic antigen,
pCR: pathologic complete response, ycT stage: clinical tumor stage after chemoradiotherapy, ycN stage: clinical node stage after chemoradiotherapy,
3D-CRT: three-dimensional conformal radiation therapy, IMRT: intensity-modulated radiation therapy, CRT: chemoradiotherapy
a There were only 395 patients with complete data for post-CRT BMI.
b There were only 501 patients with complete data for post-CRT CEA.
Table 3 - Multivariate analyses of indicators for pathological complete response to preoperative chemoradiotherapy in locally
advanced rectal cancer.
Variable p-value Odds ratio 95% CI of odds ratio
ycT stage 0-2 0.043 2.098 1.023-4.304
ycN stage 0 0.003 2.011 1.264-3.201
Interval from completion of CRT to surgery 47 weeks 0.010 1.795 1.151-2.801
Post-CRT CEA p2 ng/ml 0.038 1.579 1.026-2.432
Post-CRT DAV p5 cm 0.068 1.508 0.970-2.345
Radiation dose X50 Gy 0.086 1.515 0.942-2.436
CI: confidence interval, DAV: distance of inferior tumor margin from the anal verge, CEA: carcinoembryonic antigen, ycT stage: clinical tumor stage after
chemoradiotherapy, ycN stage: clinical node stage after chemoradiotherapy, CRT: chemoradiotherapy
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’ DISCUSSION
Unlike the majority of previous studies, which have
focused on pre-CRT factors that can predict pCR (12,13),
the present study evaluated the value of certain post-CRT
parameters and treatment variables for predicting pCR.
Using univariate and multivariate analyses, we showed that
ycT stage 0-2, yc N stage 0, interval from completion of CRT
to surgery of47 weeks and post-CRT CEAp2 ng/ml could
be applied to assess pCR post-operatively.
In our study, a favorable pCR rate of 23.2% was achieved,
which was comparable to previous reports in which CRTwas
delivered with fluoropyrimidine-based chemotherapy com-
bined with oxaliplatin (4,14,15). To improve pCR rates,
several randomized trials have been conducted to integrate
oxaliplatin into the currently widely used fluoropyrimidine-
based preoperative chemotherapy regimen. The majority of
these trials have achieved a favorable pCR rate, ranging
from 28% to 40% (5,16). However, another phase III study
showed that the addition of oxaliplatin into CRT did not
increase pCR: the pCR rate in this study was 13.9% in the
capecitabine group compared to 19.2% in the capecitabine
plus oxaliplatin group (p=0.09) (17). To the best of our
knowledge, drug dose, patient tolerance during treatment
and administration schedule all influence the achievement of
pCR. A better understanding of chemotherapy schedule as
well as the features of specific cohorts of patients might
contribute to increase pCR after CRT.
CEA is not only a prognostic factor but also a predictor for
response to preoperative CRT in LARC (18). Pretreatment
CEA level has been demonstrated as a useful marker for pCR
following preoperative CRT (13,19). However, few studies
have evaluated the value of post-CRT CEA level in assessing
pCR following preoperative CRT. Yang et al. evaluated the
association of CEA level and pCR rate in 138 patients treated
with preoperative CRT and found that a post-CRT CEA level
o2.61 ng/ml could indicate pCR postoperatively (OR=0.605,
95%CI=0.412-0.890, p=0.011)(20). Kleiman et al. showed that
post-CRT CEA levels were significantly lower in patients
with pCR (1.7 vs. 2.4 mg/L, po0.01), indicating the normal-
ization of CEA levels post-CRT was a useful predictor of
pCR in LARC (21). In our current study, a post-CRT CEA
level p2 ng/ml was significantly associated with a higher
pCR rate (28.5% vs. 20.3%, p=0.037). Although the exact
mechanism is unclear, we suppose that the lower post-CRT
CEA level implies a lower tumor burden and, subsequently,
less residual tumor in the rectum after CRT.
Several retrospective studies have emphasized the role of a
longer interval between CRT and surgery in achieving a
histological tumor response (22,23). Our study showed that
an interval of 47 weeks between completion of CRT and
surgical resection significantly increased pCR rate (26.9% vs.
18.3%, p=0.02). A previous study also reported that an interval
47 weeks could improve pCR after assessing 132 patients
with LARC (35% vs. 17%, p=0.03) (24). Recently, a large
retrospective study evaluating 17,255 patients from the
National Cancer Data Base in America indicated that an
interval greater than 8 weeks was associated with higher odds
of pCR (OR=1.12, 95% CI=1.01-1.25, p=0.040) (25). However,
the optimal timing for surgery after neoadjuvant CRT in LARC
remains controversial. Stein et al. suggested that there was no
incremental benefit from delaying surgery after CRT for tumor
regression (26). To settle this issue, a prospective randomized
trial named GRECCAR-6 was designed and the final result
aims to identify the optimal interval for delivering pCR (27).
It is well known that TNM system category is closely
associated with the prognosis of colorectal cancer. Some
previous studies have found that pretreatment clinical
N stage is an independent clinical predictor for achieving
pCR (12,28). To date, few studies have assessed whether
post-CRT TNM stage could be used to predict tumor
response to CRT (13,29). To identify useful predictors
for pCR, a recent study screened yc T stage (po0.001) and
yc N stage (po0.001) as predictors of pCR after CRT (30).
After assessing post-CRT clinical parameters, we found
similar results, namely, that ycT stage 0-2 (OR=2.098, 95%
CI=1.023-4.304, p=0.043) and ycN stage 0 (OR=2.011, 95%
CI=1.264-3.201, p=0.003) are both independent indicators for
pCR. To the best of our knowledge, lower clinical T and
N stages are associated with less tumor burden in primary
organs and lymph nodes. Further studies should be
conducted to confirm the authentic values of ycT stage and
ycN stage as indicators of pCR.
We would like to acknowledge several limitations in the
present study. The first limitation is the retrospective
methodology from a single-institution experience. Addition-
ally, some post-CRT variables, including tumor gross change,
circumferential extent of tumor and clinical stage shift after
CRT, could not be fully evaluated. Furthermore, the patients
included in our study were treated over a course of 11 years.
This is a long time and CRT regimens and methods of
pathologic assessment have changed in this period. How-
ever, even when considering the above limitations, our study
identified several post-CRT indicators for pCR. External
validation using another large database or prospective
clinical studies would be of value. Based on our results,
individualized therapy can be tailored for patients after CRT.
For instance, patients with lower rectal cancer who are
confirmed as complete responders to preoperative CRT may
choose a wait-and-see policy with avoidance of abdominal
perineal resection, as such patients may not achieve sufficient
benefit from surgery. On the contrary, patients who fail to
achieve a good response tend to have a poor prognosis and
consequently need more intensive treatments or the applica-
tion of novel therapies to minimize the possibility for local
and distant recurrences.
This large, retrospective study identified post-CRT clinical
parameters of considerable value as indicators for pCR. Post-
CRTclinical (yc) T stage 0-2, ycN stage 0, an interval from the
completion of CRT to surgery of 47 weeks and post-CRT
CEA p2 ng/ml could be useful for predicting pCR. These
indicators may help clinicians evaluate the efficiency of
preoperative CRT and formulate individualized treatment
strategies before surgery.
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